Clonotypic B Cells Are Frequent in the Blood of Myeloma Patients
| Patient Status at End of Study . | Sequential Time Points (#) . | Cells That Are Clonotypic (%) . | ||
|---|---|---|---|---|
| B Cells . | PBMC . | Absolute # ×109/L Blood . | ||
| 1. Tr | 5 | 69, 95, 93 | 24, 3, 14 | 0.1, 0.35, 0.09 |
| 95, 64 | 10, 18 | 0.05, 0.11 | ||
| 2. Deceased | 2 | 74, 74 | 19, 31 | 0.17, 0.15 |
| 3. Tr | 2 | 71, 54 | 14, 9 | 0.22, 0.12 |
| 4. Allo transplant | 6 | 45, 46, 46, 62 | 9, 9, 10, 19 | 0.12, 0.08, 0.06, 0.11 |
| 2, <0.2 | 0.6, <0.1 | 0.004, <0.000004 | ||
| 5. Off | 3 | 91, 40, 73 | 18, 8, 16 | 0.24, 0.1, 0.21 |
| 6. Tr | 3 | 60, 77, 90 | 10, 10, 50 | 0.08, 0.03, 0.1 |
| 7. Deceased | 1 | 93 | 12 | 0.06 |
| 8. Deceased | 1 | 9 | 0.9 | 0.01 |
| 9. Tr | 1 | 52 | 7 | 0.09 |
| 11. Unt | 2 | 65, 64 | 10, 6 | 0.08, 0.06 |
| 12. Auto transplant | 2 | 46, 64 | 15, 7 | 0.16, 0.13 |
| 13. Tr | 1 | 73 | 12 | 0.18 |
| 14. Tr | 2 | 28, 93 | 8, 21 | 0.03, 0.08 |
| 15. Tr | 2 | 66, 95 | 11, 13 | 0.17, 0.13 |
| 16. Tr | 1 | 56 | 13 | 0.17 |
| 17. Tr | 1 | 53 | 20 | 0.42 |
| 18. Tr | 2 | 68, 49 | 20, 18 | 0.61, 0.39 |
| 19. Tr | 1 | 50 | 21 | 0.27 |
| Mean ± SE | 66 ± 4 | 14 ± 2 | 0.15 ± .02 | |
| Normal PBMC (18 donors) | ||||
| CD19+ PBMC (55 slides) | <0.3 | |||
| Normal plasma cells (BM, 5 donors) | ||||
| CD38hiIg+ BMC (20 slides) | <0.3 | |||
| Patient Status at End of Study . | Sequential Time Points (#) . | Cells That Are Clonotypic (%) . | ||
|---|---|---|---|---|
| B Cells . | PBMC . | Absolute # ×109/L Blood . | ||
| 1. Tr | 5 | 69, 95, 93 | 24, 3, 14 | 0.1, 0.35, 0.09 |
| 95, 64 | 10, 18 | 0.05, 0.11 | ||
| 2. Deceased | 2 | 74, 74 | 19, 31 | 0.17, 0.15 |
| 3. Tr | 2 | 71, 54 | 14, 9 | 0.22, 0.12 |
| 4. Allo transplant | 6 | 45, 46, 46, 62 | 9, 9, 10, 19 | 0.12, 0.08, 0.06, 0.11 |
| 2, <0.2 | 0.6, <0.1 | 0.004, <0.000004 | ||
| 5. Off | 3 | 91, 40, 73 | 18, 8, 16 | 0.24, 0.1, 0.21 |
| 6. Tr | 3 | 60, 77, 90 | 10, 10, 50 | 0.08, 0.03, 0.1 |
| 7. Deceased | 1 | 93 | 12 | 0.06 |
| 8. Deceased | 1 | 9 | 0.9 | 0.01 |
| 9. Tr | 1 | 52 | 7 | 0.09 |
| 11. Unt | 2 | 65, 64 | 10, 6 | 0.08, 0.06 |
| 12. Auto transplant | 2 | 46, 64 | 15, 7 | 0.16, 0.13 |
| 13. Tr | 1 | 73 | 12 | 0.18 |
| 14. Tr | 2 | 28, 93 | 8, 21 | 0.03, 0.08 |
| 15. Tr | 2 | 66, 95 | 11, 13 | 0.17, 0.13 |
| 16. Tr | 1 | 56 | 13 | 0.17 |
| 17. Tr | 1 | 53 | 20 | 0.42 |
| 18. Tr | 2 | 68, 49 | 20, 18 | 0.61, 0.39 |
| 19. Tr | 1 | 50 | 21 | 0.27 |
| Mean ± SE | 66 ± 4 | 14 ± 2 | 0.15 ± .02 | |
| Normal PBMC (18 donors) | ||||
| CD19+ PBMC (55 slides) | <0.3 | |||
| Normal plasma cells (BM, 5 donors) | ||||
| CD38hiIg+ BMC (20 slides) | <0.3 | |||
Analysis was by in situ RT-PCR. Individual time points are listed sequentially in the table. The percent of PBMC and the absolute number in WBC was calculated from the percent of clonotypic B cells detected after sorting, using the percent of total PBMC that are B cells (determined by staining with anti-CD19 and FCA), and the number of mononuclear cells in blood. The mean ± SE values were calculated from the aggregate of individual time points for all patients using SigmaStat. Time points at which analysis was done are shown in Fig 6for patients 1-6, 11, 12, 15, and 18. Patient 7 was analyzed at 3 months after diagnosis, 8 was analyzed 5 years/5 months and 5 years/6 months after diagnosis while on treatment, 9 at diagnosis, 13 at diagnosis, 14 at 9 years/1 month and 9 years/3 months while on treatment, 16, 17, and 19 at diagnosis. For all samples, a minimum of 300 cells and frequently 500 to 1000 cells were viewed.
Abbreviations: Tr, treated; Off, off treatment; Unt, untreated; Allo, allogeneic; Auto, autologous.